39 / 52
Page 122
Notes:
conferenceseries
.com
Volume 8, Issue 2 (Suppl)
Chem Sci J 2017
ISSN: 2150-3494 CSJ, an open access journal
Euro Chemistry 2017
May 11-13, 2017
May 11-13, 2017 Barcelona, Spain
4
th
European Chemistry Congress
Zehra Tavşan et al., Chem Sci J 2017, 8:2(Suppl)
http://dx.doi.org/10.4172/2150-3494-C1-009Synthesis, characterization and anticancer activity of new organometallic ruthenium(II/III) complexes
Zehra Tavşan
a
, Pelin Köse Yaman
b
, BetUl Şen
c
, Cansu Sonay Karagöz
a
and
Elif Subaşıb Hulya Ayar Kayali
b,d
a,b,c,d
Dokuz Eylul University, Turkey
N
ovel organo ruthenium (II/III) complexes ([(η
6
-p-cymene)Ru(η
1
-S-TSC)Cl
2
], (1); and trans-[RuCl
2
(PPh
3
)2(η
2
-N,S-TSC)],
(2) have been synthesized from the reflux reaction of [{(η
6
-p-cymene)RuCl}
2
(μ-Cl)
2
] and [RuCl
3
(PPh
3
)
3
] with a new TSC
(2-acetyl-5-chloro-thiophene thiosemicarbazone) in methanol and benzene, respectively. TSC and both of the complexes have
been characterized by elemental analysis, UV–Vis, FT-IR and 1H NMR spectroscopy. The single crystal structure of TSC has been
determined by X-ray crystallography revealing that TSC crystallized in the monoclinic space group P21/c. The spectroscopic studies
showed that TSC is coordinated to the central metal as a neutral monodentate ligand coordinating via its thiocarbonyl sulfur atom
(C=S) in (1), whereas TSC acts as a bidentate anionic chelating ligand with azomethine nitrogen (C=N) and thiol sulfur atom in
(2). Both ruthenium complexes displayed higher antiproliferative activities against selected tumor cell lines than TSC ligand, and
significantly lower cytotoxic dose towards cancer cell lines and normal colon cell compared to cisplatin. (1) was more active against
the colon cancer while (2) was highly cytotoxic towards ovarian carcinoma cells. However, DNA and BSA binding studies for the
characterization of antitumor mechanism of ruthenium complexes indicated that these complexes interacted weakly with DNA and
BSA, as quantified by Kb in contrast with the importing into cell and accumulation in cytoplasm and then nucleus. These results
showed that the mechanism of action may be different from DNA intercalation mechanism. Also, spectral evidences showed these
complexes may prefer different transport system instead of binding with albumin. It has been observed that the complexes exhibited
different cell cycle arrest on cell lines. Furthermore, our results demonstrated that these newly synthesized ruthenium complexes
appear to be as a good antitumor drug candidate. This project has been supported by TUBITAK 215Z663.
Biography
Hulya Ayar Kayali has completed her MSc and PhD from University of Dokuz Eylul in 1997 and 2005, respectively in 2003 and postdoctoral studies from McGill
University, Canada, 2011. She works at Dokuz Eylul University from 1998 and she is a professor from 2014. She has published more than 35 papers in reputed
journals.
hulya.ayarkayali@gmail.com